Abstract
Background Sufficient community testing for suspected COVID-19 regardless of residential area is essential for a successful test-trace-isolate strategy.
Aim This study aimed to elucidate area level characteristics linked to testing rates.
Methods Free-of-charge diagnostic tests (PCR) of SARS-CoV-2 was made available to the general public in late June 2020 in Uppsala County, Sweden, at four main test stations, and to a lesser extent at other health care units. We analysed 35,794 tests performed on individuals from 346 postal codes, from 24 June to 12 October 2020.
Results We observed varying testing rates across postal code areas within Uppsala City as well as in Uppsala County. Testing rates were lower in areas characterized by longer distance to the nearest test station, lower neighbourhood deprivation index indicating higher deprivation (NDI) and higher proportion of inhabitants with foreign background. Multivariable regression models could not separate influences of foreign background and NDI on COVID-19 testing rates as these were collinear. Further, we did not detect any association between COVID-19 hospitalization rates and testing rates, indicating that underlying community infection rates did not substantially affect test frequency during this period.
Conclusion We observed that testing rates were associated with distance to test station and socioeconomic and demographic circumstances. As lower testing rates can contribute to inequity in pandemic health effects, there is an urgent need to ensure adequate test accessibility in all parts of society.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partly funded by a grant from Swedens Innovation Agency, VINNOVA (no. 2020-03173). Professor Tove Fall is the recipient of the European Research Council Starting Grant (no. 801965).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical statement All parts of the study were conducted in accordance with the Declaration of Helsinki by the World Medical Association, as revised in 2013. The study was approved by the Ethical Review Board in Sweden (DNR 2020-04210). Informed consent was not obtained from individuals tested for COVID-19 since only information on aggregate group level was extracted.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared first authorship
Data Availability
The data in this study originate from Statistics Sweden, electronic medical records database maintained by Uppsala City Council, and Postnummerservice AB. Restrictions apply to the availability of these data, which were used under license and ethical approval and are not publicly available. Data are however available from the authors upon reasonable request and with written permission from the Swedish Ethical Review Authority.
